76250
Off
suraksha diagnostics logo

Suraksha Diagnostic IPO

  • Status: Closed
  • RHP:
  • ₹ 14,280 / 34 shares

    Minimum Investment

IPO Listing Details

  • Listing Date

    06 Dec 2024

  • Listing Price

    ₹437.00

  • Listing Change

    -0.91%

  • Last Traded Price

    ₹384.10

IPO Details

  • Open Date

    29 Nov 2024

  • Close Date

    03 Dec 2024

  • IPO Price Range

    ₹ 420 to ₹ 441

  • IPO Size

    ₹ 846.25 Cr

  • Listing Exchange

    BSE NSE

  • Listing Date

    06 Dec 2024

With just a few clicks, Invest in IPOs!

+91

By proceeding, you agree to all T&C*

hero_form

Suraksha Diagnostic IPO Subscription Status

Last Updated: 03 December 2024 6:56 PM by 5Paisa

Suraksha Diagnostic IPO is set to open on 29 November 2024 and will close on 3 December 2024. Suraksha Diagnostic is a prominent provider of pathology, radiology, and medical consultancy services. 

The IPO is entirely an offer for sale of 1.92 Cr shares aggregating ₹846.25 Cr. The price range is set between ₹420 to ₹441 per share and the lot size is 34 shares. 

The allotment is scheduled to be finalised on 4 December 2024. It will go public on NSE SME, with a tentative listing date of 6 December 2024.

ICICI Securities Ltd, Nuvama Wealth Management Ltd and SBI Capital Markets Ltd are the book running lead managers while Kfin Technologies Ltd is the registrar. 
 

Suraksha IPO Size

Types Size
Total IPO Size ₹846.25 Cr
Offer For Sale ₹846.25 Cr
Fresh Issue -

 

Suraksha IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 34 ₹14,994
Retail (Max) 13 442 ₹194,922
S-HNI (Min) 14 476 ₹209,916
S-HNI (Max) 66 2,244 ₹989,604
B-HNI (Min) 67 2,278 ₹1,004,598

 

Suraksha IPO Reservation

Investors Category Subscription (times) Shares Offered Shares bid for Total Amount (Cr.)
QIB 1.74 38,37,867     66,67,332 294.029
NII (HNI) 1.40 28,78,400 40,42,124 178.258
Retail 0.94 67,16,266     62,99,078 277.789
Total 1.27 1,34,32,533 1,70,08,534 750.076

 

Suraksha IPO Anchor Allocation

Anchor Bid Date 28 November, 2024
Shares Offered 5,756,797
Anchor portion Size (In ₹ Cr.) 253.87
Anchor lock-in period end date for 50% shares (30 Days) 03 January, 2025
Anchor lock-in period end date for remaining shares (90 Days) 04 March, 2025

The IPO proceeds will not be utilized for the company’s operations or growth plans. Instead, the purpose of the IPO is to enable existing shareholders to divest their holdings and exit the business.
 

Suraksha Diagnostic, is a prominent provider of pathology, radiology, and medical consultancy services. With a robust infrastructure comprising a central reference laboratory, eight satellite labs, and 215 customer touchpoints—including 49 diagnostic centers and 166 sample collection facilities—the company operates across West Bengal, Bihar, Assam, and Meghalaya. Its 44 diagnostic centers also house 120 polyclinics with over 750 doctors, offering both online and offline medical consultations. Leveraging advanced systems like Laboratory Information Management System (LIMS), Radiology Information System (RIS), Picture Archive Communication System (PACS), and Enterprise Resource Planning (ERP), Suraksha ensures streamlined operations and reduced turnaround times.

The company specializes in vaccination services and customized testing packages for early disease detection, utilizing digital pathology and AI-driven blood test generation. Suraksha’s competitive edge lies in its integrated service model, advanced clinical infrastructure, and a strong focus on quality, ensuring high customer retention in fragmented eastern and northeastern Indian markets.

Peers

Dr. Lal PathLabs
Metropolis Healthcare
Thyrocare
Vijaya Diagnostic

Profit and Loss

Balance Sheet

Particulars (in Rs. Crores) FY24 FY23 FY22
Revenue 222.26 193.69 225.77
EBITDA 73.62 47.48 65.25
PAT 23.13 6.07 20.82
Particulars (in Rs. Crores) FY24 FY23 FY22
Total Assets 300.21 281.20 275.96
Share Capital 6.90 6.90 6.90
Total Borrowings 8.64 14.01 19.03
Particulars (in Rs. Crores) FY24 FY23 FY22
Net Cash Generated From / (used in) operating activities 60.48 44.10 57.82
Net Cash Generated From / (used in) Investing Activities -35.00 -20.80 -43.28
Net Cash Generated From / (used in) financing activities -25.13 -24.33 -14.28
Net Increase (Decrease) In Cash And Cash Equivalents 0.36 -1.03 0.26

Strengths

1. Extensive network across eastern and northeastern India.
2. Integrated pathology, radiology, and consultancy services under one roof.
3. Advanced technology platforms like LIMS, RIS, PACS, and ERP.
4. Strong focus on quality ensures high customer retention.
5. Experienced management team with deep industry expertise.

Risks

1. Limited geographical presence outside eastern and northeastern India.
2. Heavy reliance on technological systems for operations.
3. High competition from national diagnostic chains in expanding markets.
4. Dependence on a fragmented market for growth opportunities.
5. Vulnerability to economic and regulatory changes in the healthcare sector.
 

Will You Apply for Suraksha Diagnostic IPO?

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

FAQs

Suraksha Diagnostic IPO opens from 29 November to 3 December 2024.

The size of Suraksha Diagnostic IPO is ₹846.25 Cr.

The price band of Suraksha Diagnostic IPO is fixed at ₹420 to ₹441 per share. 

To apply for Suraksha Diagnostic IPO, follow the steps given below:

● Login to your 5paisa account and select the issue in the current IPO section    
● Enter the number of lots and the price at which you wish to apply for the Suraksha Diagnostic  IPO.    
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.    

You will receive a mandate notification to block funds in your UPI app.
 

The minimum lot size of Suraksha Diagnostic IPO is 34 shares and the investment required is ₹14,994.
 

The share allotment date of Suraksha Diagnostic IPO is 4 December 2024

The Suraksha Diagnostic IPO will be listed on 6 December 2024.

ICICI Securities Ltd, Nuvama Wealth Management Ltd and SBI Capital Markets Ltd are the book running lead managers of Suraksha Diagnostic IPO.

The company will not receive any proceeds from the Offer. All proceeds will be directed to the Selling Shareholders, based on the number of shares each shareholder sells through the Offer.